ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM Immupharma Plc

2.10
-0.08 (-3.67%)
Last Updated: 15:32:25
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.08 -3.67% 2.10 2.01 2.10 2.25 2.10 2.20 2,011,776 15:32:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.84 7M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.18p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 3.78p.

Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £7 million. Immupharma has a price to earnings ratio (PE ratio) of -1.84.

Immupharma Share Discussion Threads

Showing 7226 to 7248 of 39125 messages
Chat Pages: Latest  293  292  291  290  289  288  287  286  285  284  283  282  Older
DateSubjectAuthorDiscuss
12/12/2017
09:45
There have been pauses and consolidation at 80p 100p and 130p and all have been utterly smashed before the move higher. This feels like another pause at 170p before the inevitable next step up.

I fancy the next leg to go straight through 200p without a backward glance.

qazwsxedc69
12/12/2017
09:21
Few more buys should tick up again hopefully
aussieb3
12/12/2017
09:21
Mostly buys but no share price rise, looks like a few sell orders coming in, steady rises here better than spikes, which are sold into, a few new aliases appearing, the herd has arrived!

Buy..hold and forget about these until early 2018

ny boy
12/12/2017
09:12
And if anyone wants to nominate me for the 'stating the bleeding obvious' award - then I would be happy to accept it (I have a speech already prepared)
hamhamham1
12/12/2017
08:55
IMHO. This share is only going to go one way (up) for the next month or two. Its more a question of what angle the climb takes. There may be the odd RNS to inform last drug administered and last patient readings taken. Then the big date is when the results data is released. But as I said, until then its upwards as anticipations and expectations mount. DYOR.
hamhamham1
12/12/2017
08:43
valuations given by brokers usually are very conservative
divinessence
12/12/2017
08:40
I don't reckon that QS I reckon that valuation is very conservative :-)
spawny100
12/12/2017
08:39
Yes a few new names popping up amongst regulars. Not to worry just hang on to your shares if they try to shake weak holders out imo
spawny100
12/12/2017
08:37
So £8.79p you reckon if successful Phase III? with bid premium on top maybe if a major wanted to take them out? DYOR etc....happy to play that numbers game!
qs99
12/12/2017
08:35
Feels like the herd are coming...not sure if that's a good thing though but given market cap here the results and institutions will be the price shifters here
costapacket
12/12/2017
08:32
This time next year Rodney!:)
uncleoswald
12/12/2017
08:29
Yep that's how I read it HK
spawny100
12/12/2017
08:29
Correct Spawny They are suggesting it will be 443p on successful phase III.....PLUS 50p PLUS 386p.In other words 879p.Boom time
herschel k
12/12/2017
08:17
well people said that around the £1.30 mark!
qs99
12/12/2017
08:13
I think a few people are getting ahead of themselves. Think it will be a bit up and down around this mark till the results come now.
ourbr3tt0
12/12/2017
07:52
come jan/feb we will be above £5
falia
12/12/2017
07:50
That 386p is only the value of the milestone payments per share if I read it correctly i.e ON TOP of the valuation
spawny100
12/12/2017
07:44
Fincap says 386p


Magic bullet with butterfly wings?


386p
Boom boom 💥

vatpaul
12/12/2017
07:35
200 today lol. Ny boy your being outramped
davr0s
12/12/2017
07:33
vatpaul
Member since: 21 Nov 2017

Just wondering when you started buying these?

ny boy
12/12/2017
07:26
Boomtime here. VAL as well today and poss AOR. Bio is place to be right now.
spawny100
12/12/2017
07:15
Immupharma (IMM) is a drug discovery company whose lead product Lupuzor, is in Phase III trials for the treatment of Systemic Lupus Erythematous (SLE). Previous IIb trial demonstrated both efficacy and safety through novel immune system modulation that offers benefits to the only approved treatment, a monoclonal antibody (mAb) called Benlysta with £400m annual sales. Phase III pivotal study readout (n=200) expected Q1-18 (finnCap est. approval of 63%) follows on from Lupuzor being given Special Protocol Assessment (SPA) status by the FDA with existing global patent protection until 2032. Blockbuster status (sales >$1bn) could be achieved within 8 years and historical licence deal (Cephalon, 2009) suggestive of licence/partner agreement potential. Unusual upside potential from binary readout leads us to initiate coverage with a Buy recommendation and 237p price target (increasing 87% on +ve Phase III, which excludes the value of potential upfront (c.50p) and milestone payments that could amount to c£500m or 386p per share).


Will be over 200 today for sure

vatpaul
12/12/2017
06:27
"To be considered a responder a patient has to have an improvement in at least 6 of the 24 measures."I imagine improvement between many of the measures are highly correlated. They will know the drop out rate.
wigwammer
Chat Pages: Latest  293  292  291  290  289  288  287  286  285  284  283  282  Older

Your Recent History

Delayed Upgrade Clock